WO1996012011A1 - Lignee cellulaire a reporteurs - Google Patents
Lignee cellulaire a reporteurs Download PDFInfo
- Publication number
- WO1996012011A1 WO1996012011A1 PCT/EP1995/004032 EP9504032W WO9612011A1 WO 1996012011 A1 WO1996012011 A1 WO 1996012011A1 EP 9504032 W EP9504032 W EP 9504032W WO 9612011 A1 WO9612011 A1 WO 9612011A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression
- gene
- reporter gene
- die
- cells
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims abstract description 20
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims abstract description 20
- 230000001404 mediated effect Effects 0.000 claims abstract description 17
- 108010018242 Transcription Factor AP-1 Proteins 0.000 claims abstract description 6
- 102100023132 Transcription factor Jun Human genes 0.000 claims abstract description 6
- 230000003314 glucocorticoidlike Effects 0.000 claims abstract description 4
- 238000012544 monitoring process Methods 0.000 claims abstract description 4
- 230000004936 stimulating effect Effects 0.000 claims abstract description 4
- 238000010998 test method Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 61
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 29
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 29
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 26
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 19
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 19
- 239000000854 Human Growth Hormone Substances 0.000 claims description 18
- 102000040945 Transcription factor Human genes 0.000 claims description 8
- 108091023040 Transcription factor Proteins 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 108010031345 placental alkaline phosphatase Proteins 0.000 claims description 3
- 230000000464 effect on transcription Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 description 14
- 239000003862 glucocorticoid Substances 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 238000003556 assay Methods 0.000 description 9
- 229940037128 systemic glucocorticoids Drugs 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
- 102100023413 GRB2-related adapter protein Human genes 0.000 description 3
- 101000829735 Homo sapiens GRB2-related adapter protein Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102100035384 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 Human genes 0.000 description 2
- 101710098657 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108700025907 jun Genes Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Definitions
- This invention relates to a reporter cell line and is particularly, though not exclusively,
- Glucocorticoids exert profound effects on the inflammatory and immune responses. They
- Agonistic glucocorticoids inhibit transcription of these genes by interfering with the API transcription factor, the
- GR hormone activated glucocorticoid receptor
- Glucocorticoid induces a combination of high levels of parathyroid hormone, PTH, and
- a cell line including a
- first reporter gene arranged to express an assayable first gene product, expression of the
- first reporter gene being mediated by a transcription factor
- second reporter gene
- the invention provides a cell line including a first reporter gene arranged to express an assayable first gene product, expression of d e first reporter gene being AP-1 mediated, and a second reporter gene arranged to express a second assayable gene
- the present invention provides a convenient one cell line-based assay system which
- the cell line allows the testing of two activities in a single cell whereas previously two cell lines would be required.
- the cell line is derived from human, more preferably HeLa cells.
- One of the reporter genes may be arranged to express an alkaline phosphatase such as
- human placental alkaline phosphatase and the other reporter gene may be arranged to
- a method of testing a compound for glucocorticoid-like activity comprising providing cells in accordance with
- API activity may be stimulated by TPA or EGF.
- Fig. 1A shows the nucleotide sequence of d e five API responsive elements inserted in tandem upstream of the mouse mammary tumour virus long terminal repeat (MMTN
- ALP phosphatase
- Fig IB shows the ALP reporter vector 5AP ⁇ T-ALP containing the nucleotide sequence
- Fig 2 shows the glucocorticoid receptor controlled reporter vector MMTV-hGH2
- hGH human growth hormone polypeptide
- Fig.3 illustrates the effect of dexamethasone on API -dependent ALP expression and GR dependent hGH reporter gene transactivation, respectively and the effects of Epidermal
- EGF Growth Factor
- Fig. 4 illustrates the effect of different corticosteroids on glucocorticoid receptor dependent transactivation of hGH expression and repression of AP-1 -dependent ALP
- HeLa tk " cells were initially stably transformed using conventional techniques with a
- reporter vector 5APNT-ALP comprising five API response elements arranged in tandem
- Figs. 1A and B show that secretion of the ALP protein into the medium is indicative of AP-1 mediated transcription.
- Fig. 1A shows that secretion of the ALP protein into the medium is indicative of AP-1 mediated transcription.
- MMTV terminal repeat
- alkaline phosphatase ALP
- 5APNT-ALP alkaline phosphatase
- ALP is underlined.
- the resulting cells were termed GRAP cells.
- the level of ALP reporter protein expressed and secreted into d e medium can be determined indirectly by a chemiluminescence assay.
- the facility to use a chemiluminescence assay The facility to use a chemiluminescence assay.
- me ALP based reporter assay particularly convenient to use compared to intracellular reporters such as chloramphenicol acetyltransferase (CAT) and luciferase
- CAT chloramphenicol acetyltransferase
- the reporter vector MMTV-hGH2 comprises a GR-regulated promoter (MMTV) fused to a reporter
- hGH human growth hormone
- the level of glucocorticoid- induced hGH expression is determined immunologically by a Delfia assay (Wallac OY,
- the GRAPF cells contain two exogenous transcription units whose reporter genes
- the ALP transcription unit is controlled by, and responds to,
- d e hGH transcription unit responds to ligand activated GR resulting in an
- TPA or EGF induced API activity indirectly determined by increased ALP
- glucocorticoids as well as dieir potency as inhibitors of API -dependent transcription, indirectly reflecting their potency as anti-inflammatory drugs.
- the expression of the ALP reporter protein in these cells is controlled by the API transcription factor, induced by phorbol esters such as TPA or die growth factor EGF.
- inflammatories was demonstrated using die synthetic glucocorticoid dexamethasone.
- GRAPF cells were seeded in 96-well microtiter plates in
- the relative levels of ALP expressed were determined by a chemiluminescent assay as follows: a lO ⁇ l aliquot of die cell culture medium was mixed wid 200 il of assay buffer (lOmM die ianolamine pH 10.; ImM MgCl 2 and 0.5mM AMPPD) in accordance with
- Luminoskan Labsy stems, Finland The setting of the Luminoskan luminometer was
- the alkaline phosphatase activity is expressed in light units (LU).
- hGH expression was monitored immunologically with the Delfia assay mentioned above.
- the cells were treated wid lOOng/ml EGF to induce the /as and jun genes (and
- reporter expression is induced in a hormone-dependent manner irrespective of the
- the reporter cell line and process of die invention may be used to test a wide variety of
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
On décrit une lignée cellulaire comprenant un premier gène reporteur conçu pour exprimer un premier produit génique dosable, l'expression de ce premier gène reporteur étant induite par AP-1, ainsi qu'un second gène reporteur conçu pour exprimer un second produit génique dosable, l'expression de ce second gène reporteur étant induite par le récepteur glucocorticoïde (GR). On décrit également un procédé de recherche d'un composé pour l'activité de type glucocorticoïde de celui-ci, consistant à fournir des cellules selon le premier aspect de l'invention, à stimuler l'activité AP-1 dans ces cellules, à mettre celles-ci en contact avec le composé puis à contrôler l'expression des produits des premier et second gènes.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38420/95A AU3842095A (en) | 1994-10-14 | 1995-10-12 | Reporter cell line |
JP8512938A JPH10509584A (ja) | 1994-10-14 | 1995-10-12 | リポーター細胞株 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9420735A GB9420735D0 (en) | 1994-10-14 | 1994-10-14 | Reporter cell line |
GB9420735.4 | 1994-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996012011A1 true WO1996012011A1 (fr) | 1996-04-25 |
Family
ID=10762844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/004032 WO1996012011A1 (fr) | 1994-10-14 | 1995-10-12 | Lignee cellulaire a reporteurs |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPH10509584A (fr) |
AU (1) | AU3842095A (fr) |
GB (1) | GB9420735D0 (fr) |
WO (1) | WO1996012011A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE29916160U1 (de) | 1999-09-14 | 2000-03-09 | Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath | Modulation der Transkription von Genen in vaskulären Zellen |
WO2000023581A1 (fr) * | 1998-10-22 | 2000-04-27 | Signal Pharmaceuticals, Inc. | Systeme a double rapporteur et techniques d'utilisation |
KR20030046896A (ko) * | 2001-12-07 | 2003-06-18 | 학교법인 포항공과대학교 | 당질코르티코이드에 의해 발현이 조절되는 재조합 리포터유전자를 가지는 형질전환 세포주 및 이를 이용한당질코르티코이드 유사물질 및 저해물질의 생물학적검색방법 |
US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005447A1 (fr) * | 1990-09-21 | 1992-04-02 | The Salk Institute For Biological Studies | ANTAGONISME FONCTIONNEL ENTRE LA PROTO-ONCOPROTEINE c-JUN ET DES RECEPTEURS D'HORMONES |
WO1994001584A1 (fr) * | 1992-07-06 | 1994-01-20 | President And Fellows Of Harvard College | Procedes et necessaires de diagnostic pour determiner la toxicite utilisant des promoteurs de stress bacteriens fusionnes a des genes rapporteurs |
WO1994017208A1 (fr) * | 1993-01-21 | 1994-08-04 | President And Fellows Of Harvard College | Methodes et trousses de diagnostic faisant appel aux promoteurs de stress des mammiferes pour determiner la toxicite d'un compose |
WO1994023041A2 (fr) * | 1993-04-02 | 1994-10-13 | Ribogene, Inc. | Procede d'inactivation selective de replication virale |
-
1994
- 1994-10-14 GB GB9420735A patent/GB9420735D0/en active Pending
-
1995
- 1995-10-12 JP JP8512938A patent/JPH10509584A/ja active Pending
- 1995-10-12 WO PCT/EP1995/004032 patent/WO1996012011A1/fr active Application Filing
- 1995-10-12 AU AU38420/95A patent/AU3842095A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005447A1 (fr) * | 1990-09-21 | 1992-04-02 | The Salk Institute For Biological Studies | ANTAGONISME FONCTIONNEL ENTRE LA PROTO-ONCOPROTEINE c-JUN ET DES RECEPTEURS D'HORMONES |
WO1994001584A1 (fr) * | 1992-07-06 | 1994-01-20 | President And Fellows Of Harvard College | Procedes et necessaires de diagnostic pour determiner la toxicite utilisant des promoteurs de stress bacteriens fusionnes a des genes rapporteurs |
WO1994017208A1 (fr) * | 1993-01-21 | 1994-08-04 | President And Fellows Of Harvard College | Methodes et trousses de diagnostic faisant appel aux promoteurs de stress des mammiferes pour determiner la toxicite d'un compose |
WO1994023041A2 (fr) * | 1993-04-02 | 1994-10-13 | Ribogene, Inc. | Procede d'inactivation selective de replication virale |
Non-Patent Citations (4)
Title |
---|
ALKSNIS ET AL.: "High level expression of functional full length and truncated glucocorticoid receptor in chinese hamster ovary cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 16, 1991, MD US, pages 10078 - 10085, XP002000023 * |
JONAT ET AL.: "Antitumor promotion and atiinflamation: downmodulation of AP-1 (FOS/JUN) activity by glucocorticoid hormone", CELL, vol. 62, 1990, NA US, pages 1189 - 1204, XP002000021 * |
SCHÜLE ET AL.: "Functional antagonism between oncoprotein c-Jun and the GCR", CELL, vol. 62, 1990, NA US, pages 1217 - 1226, XP002000022 * |
YANG-YEN ET AL.: "Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction", CELL, vol. 62, 1990, NA US, pages 1205 - 1215, XP002000020 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023581A1 (fr) * | 1998-10-22 | 2000-04-27 | Signal Pharmaceuticals, Inc. | Systeme a double rapporteur et techniques d'utilisation |
DE29916160U1 (de) | 1999-09-14 | 2000-03-09 | Cardiogene Gentherapeutische Systeme AG, 40699 Erkrath | Modulation der Transkription von Genen in vaskulären Zellen |
US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
US7186556B2 (en) | 1999-09-14 | 2007-03-06 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
KR20030046896A (ko) * | 2001-12-07 | 2003-06-18 | 학교법인 포항공과대학교 | 당질코르티코이드에 의해 발현이 조절되는 재조합 리포터유전자를 가지는 형질전환 세포주 및 이를 이용한당질코르티코이드 유사물질 및 저해물질의 생물학적검색방법 |
Also Published As
Publication number | Publication date |
---|---|
JPH10509584A (ja) | 1998-09-22 |
GB9420735D0 (en) | 1994-11-30 |
AU3842095A (en) | 1996-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Psarra et al. | The mitochondrion as a primary site of action of steroid and thyroid hormones: presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells | |
Cochran et al. | Molecular cloning of gene sequences regulated by platelet-derived growth factor | |
AU655943B2 (en) | Functional antagonism between proto-oncoprotein c-jun and hormone receptors | |
Cavailles et al. | Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells | |
Harding et al. | The monomer-binding orphan receptor Rev-Erb represses transcription as a dimer on a novel direct repeat | |
Manna et al. | Assessment of the role of activator protein-1 on transcription of the mouse steroidogenic acute regulatory protein gene | |
McDonnell et al. | Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. | |
Librach et al. | Interleukin-1 beta regulates human cytotrophoblast metalloproteinase activity and invasion in vitro. | |
Russell et al. | Egr-1 induction in rat granulosa cells by follicle-stimulating hormone and luteinizing hormone: combinatorial regulation by transcription factors cyclic adenosine 3′, 5′-monophosphate regulatory element binding protein, serum response factor, sp1, and early growth response factor-1 | |
Bayne et al. | Increased expression of the FIGLA transcription factor is associated with primordial follicle formation in the human fetal ovary | |
Scheller et al. | Glucocorticoid and thyroid hormone receptors in mitochondria of animal cells | |
Krishnan et al. | Stimulation of 1, 25‐dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors | |
Chandran et al. | Glucocorticoid repression of the mouse gonadotropin-releasing hormone gene is mediated by promoter elements that are recognized by heteromeric complexes containing glucocorticoid receptor | |
Lohrke et al. | Detection and functional characterisation of the transcription factor peroxisome proliferator-activated receptor gamma in lutein cells | |
Sherman et al. | Role of signal transducers and activators of transcription 1 and-3 in inducible regulation of the human angiotensinogen gene by interleukin-6 | |
Schroen et al. | Inhibition of rabbit collagenase (matrix metalloproteinase‐1; MMP‐1) transcription by retinoid receptors: Evidence for binding of RARs/RXRs to the− 77 AP‐1 site through interactions with c‐Jun | |
Sellitti et al. | lac repressor blocks in vivo transcription of lac control region DNA. | |
Seely et al. | Transcriptional regulation of dehydroepiandrosterone sulfotransferase (SULT2A1) by estrogen-related receptor α | |
Bailey et al. | Characterization and functional analysis of cAMP response element modulator protein and activating transcription factor 2 (ATF2) isoforms in the human myometrium during pregnancy and labor: identification of a novel ATF2 species with potent transactivation properties | |
Chedid et al. | Activation of AP-1 by IL-1 and phorbol esters in T cells. Role of protein kinase A and protein phosphatases. | |
WO1996012011A1 (fr) | Lignee cellulaire a reporteurs | |
Begeot et al. | Regulation of expression of the CYP11A (P450scc) gene in bovine ovarian luteal cells by forskolin and phorbol esters | |
Sawatsri et al. | Retinoic acid suppresses interleukin-6 production in human endometrial cells | |
Monla et al. | Cell type-specific regulation of transcription by cyclic adenosine 3,'5'-monophosphate-responsive elements within the calcitonin promoter. | |
Kapila et al. | Induction of MMP‐1 (collagenase‐1) by relaxin in fibrocartilaginous cells requires both the AP‐1 and PEA‐3 promoter sites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1019970702443 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970702443 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |